Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 10Bone Neoplasms 9Sarcoma 8Neoplasms 3Multiple Myeloma 3Sarcoma, Kaposi 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Anemia 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Venous Thromboembolism 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Psoriasis 1Prostatic Neoplasms 1Progressive Gastrointestinal Stromal Tumor 1Piebaldism 1Pancreatic Neoplasms 1Pain, Intractable 1

Interventions

nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Piebaldism × Sarcoma × Clear all
NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Novartis

Phase 4 Completed
57 enrolled 8 charts
GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡